Nocturne Acquisition Corporation
MBTC
NASDAQ Capital Market11.66
USD
+0.46
- -
CIK
0001837344
ISIN
KYG6580S1140
CUSIP
G6580S114
Return %
Stock
S&P500
1Y
5.62
26.84
3Y
19.16
77.03
5Y
19.16
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Henry Monzon
- Full Time Employees
- 2
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 3 Germay Drive Wilmington DE United States of America 19804
- IPO Date
- May 5, 2021
- CIK
- 0001837344
- Website
- nocturnecorp.com
- Similar Companies
- Business
- Nocturne Acquisition Corporation (NASDAQ:MBTC) is a blank check company formed as a Cayman Islands exempted company whose sole purpose is to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses, with no current significant operations or revenue generation. Incorporated on October 28, 2020, and headquartered in Wilmington, Delaware, with additional addresses referenced in Santa Ana, California, and La Jolla, California, the company targets opportunities particularly in disruptive technology sectors such as blockchain, artificial intelligence, and medical innovation; it maintains a lean structure led by CEO and Chairman Henry Monzon and CFO Ka Seng Ao. In a major recent development, the company pursued a reverse merger with Cognos Therapeutics Inc., a developer of implantable drug delivery systems like the SINNAIS smart pump for neurological treatments including brain cancer, filing a Form S-4 registration statement and engaging Chardan as advisor, but terminated the transaction in April 2024 due to inability to meet conditions, leading to public share redemption at approximately $11.79 per share, Nasdaq delisting via Form 25, and SEC registration termination via Form 15.
Chardan Engaged to Facilitate Nocturne Acquisition Corporation's Business Combination with Cognos Therapeutics, Inc., Paving the Way for NASDAQ Listing
Nocturne Acquisition Corporation Announces Filing of a Registration Statement on Form S-4 in Connection with its Proposed Business Combination with Cognos